Results overview: Found 2 records in 0.02 seconds.
Articles, 2 records found
Articles 2 records found  
1.
12 p, 744.6 KB First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) / Carrato, Alfredo (Instituto Ramón y Cajal de Investigación Sanitaria) ; Abad, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Massuti, Bartomeu (Hospital General de Alicante) ; Grávalos, Cristina (Hospital 12 de Octubre) ; Escudero, Pilar (Hospital Clínico Lozano Blesa) ; Longo Muñoz, Federico (Instituto Ramón y Cajal de Investigación Sanitaria) ; Manzano, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gómez, Auxiliadora (Instituto Maimónides de Investigación Biomédica) ; Safont, María José (Hospital General de València) ; Gallego, Javier (Hospital General Universitario de Elche) ; García-Paredes, Beatriz (Hospital San Carlos) ; Pericay, Carles (Corporació Sanitària Parc Taulí) ; Dueñas, Rosario (Complejo Hospitalario de Jaén) ; Rivera, Fernando (Hospital Marqués de Valdecilla) ; Losa, Ferrán (Hospital General de l'Hospitalet) ; Valladares Ayerbes, Manuel (Hospital Universitario da Coruña) ; González, Encarnación (Hospital Virgen de las Nieves) ; Aranda, Enrique (Instituto Maimónides de Investigación Biomédica) ; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) ; Universitat Autònoma de Barcelona
Abstract Background: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. [...]
2017 - 10.1016/j.ejca.2017.04.024
European Journal of Cancer, Núm. 81 (2017) , p. 191-202  
2.
12 p, 942.4 KB BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer / Karachaliou, Niki (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Codony-Servat, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Teixidó, Cristina (Pangaea Biotech (Barcelona, Catalunya)) ; Pilotto, Sara (University of Verona (Itàlia)) ; Drozdowskyj, Ana (Pivotal (Madrid)) ; Codony-Servat, Carles (Pangaea Biotech (Barcelona, Catalunya)) ; Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ; Molina-Vila, Miguel Ángel (Pangaea Biotech (Barcelona, Catalunya)) ; Bertrán-Alamillo, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Gervais, Radj (Centre François Baclesse (Caen, França)) ; Massuti, Bartomeu (Hospital General de Alicante) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Majem, Margarita (Hospital de Sant Pau (Barcelona, Catalunya)) ; Felip Font, Enriqueta (Hospital Vall d'Hebron (Barcelona, Catalunya)) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ; Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; González-Cao, María (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Morales-Espinosa, Daniela (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Verlicchi, Alberto (Ospedale Santa Maria delle Croci (Ravenna, Itàlia)) ; Crisetti, Elisabetta (Institute of Respiratory Diseases. University of Foggia (Itàlia)) ; Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Santarpia, Mariacarmela (Human Pathology Department. University of Messina (Itàlia)) ; Ramírez, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, Joaquim (Hospital Josep Trueta, Girona. Institut Català d'Oncologia) ; Cardona Zorrilla, Andrés Felipe (Instituto de Oncología de Clínica del Country (Bogotá, Colòmbia)) ; De Marinis, Filippo (Istituto Europeo di Oncologia (Milà, Itàlia)) ; López-Vivanco, Guillermo (Hospital de Cruces (Barakaldo, Biscaia)) ; Sánchez, José Miguel (Hospital Universitario de la Princesa (Madrid)) ; Vergnenegre, Alain (Hôpital du Cluzeau (Limoges, França)) ; Sánchez Hernández, José Javier (Universidad Autónoma de Nuevo León (Mèxic)) ; Sperduti, Isabella (Istituto Regina Elena Cancer Institute (Roma, Itàlia)) ; Bria, Emilio (University of Verona (Itàlia)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abstract. BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC trial. [...]
2015 - 10.1038/srep17499
Scientific reports, Vol. 7 (December 2015)  

See also: similar author names
3 Massuti, Bartomeu
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.